Literature DB >> 27104071

PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents.

Kiran M Kanth1, Guillermo E Solorzano1, Myla D Goldman1.   

Abstract

Entities:  

Year:  2016        PMID： 27104071      PMCID： PMC4828683          DOI： 10.1212/CPJ.0000000000000202

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  7 in total

1.  An unusual complication of immunosuppression in myasthenia gravis: progressive multifocal leukoencephalopathy.

Authors:  Muhteşem Gedizlioglu; Pinar Coban; Pinar Ce; Izlem Evren Sivasli
Journal:  Neuromuscul Disord       Date:  2008-12-02       Impact factor: 4.296

Review 2.  Update on progressive multifocal leukoencephalopathy.

Authors:  Israel Steiner; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2012-12       Impact factor: 5.081

3.  Mycophenolate mofetil associated with progressive multifocal leukoencephalopathy with successful outcome.

Authors:  Driss El Kabbaj; Mohammed Hassani; Mouncif Kadiri; Jamal Mounach; Hamid Ouhabi; Charki Haimeur; Zouhir Oualim
Journal:  Saudi J Kidney Dis Transpl       Date:  2012-07

Review 4.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

5.  Progressive multifocal leukoencephalopathy in myasthenia gravis.

Authors:  D M Dawson
Journal:  Ann Neurol       Date:  1982-02       Impact factor: 10.422

6.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis.

Authors:  David B Clifford; Beau Ances; Craig Costello; Shari Rosen-Schmidt; Magnus Andersson; Deborah Parks; Arie Perry; Raju Yerra; Robert Schmidt; Enrique Alvarez; Kenneth L Tyler
Journal:  Arch Neurol       Date:  2011-05-09

Review 7.  Rituximab and immune deficiency: case series and review of the literature.

Authors:  Blanka Kaplan; Yelena Kopyltsova; Amrita Khokhar; Fung Lam; Vincent Bonagura
Journal:  J Allergy Clin Immunol Pract       Date:  2014-08-07
  7 in total
  9 in total

Review 1.  Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.

Authors:  Grayson Beecher; Brendan Nicholas Putko; Amanda Nicole Wagner; Zaeem Azfer Siddiqi
Journal:  Drugs       Date:  2019-03       Impact factor: 9.546

2.  Efficacy and Safety of Low-Dose Rituximab in Anti-MuSK Myasthenia Gravis Patients: A Retrospective Study.

Authors:  Xin Meng; Ziling Zeng; Yunda Wang; Shuai Guo; Chunjuan Wang; Baojie Wang; Shougang Guo
Journal:  Neuropsychiatr Dis Treat       Date:  2022-05-03       Impact factor: 2.989

3.  High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.

Authors:  Raffi Topakian; Fritz Zimprich; Stephan Iglseder; Norbert Embacher; Michael Guger; Karl Stieglbauer; Dieter Langenscheidt; Jakob Rath; Stefan Quasthoff; Philipp Simschitz; Julia Wanschitz; David Windisch; Petra Müller; Dierk Oel; Günther Schustereder; Stefan Einsiedler; Christian Eggers; Wolfgang Löscher
Journal:  J Neurol       Date:  2019-01-16       Impact factor: 4.849

Review 4.  Myasthenia gravis and infectious disease.

Authors:  Nils Erik Gilhus; Fredrik Romi; Yu Hong; Geir Olve Skeie
Journal:  J Neurol       Date:  2018-01-25       Impact factor: 4.849

5.  Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.

Authors:  Fanny Huynh Du; Elizabeth A Mills; Yang Mao-Draayer
Journal:  Auto Immun Highlights       Date:  2017-11-16

6.  The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis.

Authors:  Elena Cortés-Vicente; Ricard Rojas-Garcia; Jordi Díaz-Manera; Luis Querol; Carlos Casasnovas; Antonio Guerrero-Sola; José Luis Muñoz-Blanco; José Eulalio Bárcena-Llona; Celedonio Márquez-Infante; Julio Pardo; Eva María Martínez-Fernández; Mercedes Usón; Pedro Oliva-Nacarino; Teresa Sevilla; Isabel Illa
Journal:  Ann Clin Transl Neurol       Date:  2018-04-14       Impact factor: 4.511

Review 7.  Understanding the burden of refractory myasthenia gravis.

Authors:  Christiane Schneider-Gold; Tim Hagenacker; Nico Melzer; Tobias Ruck
Journal:  Ther Adv Neurol Disord       Date:  2019-03-01       Impact factor: 6.570

Review 8.  New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis.

Authors:  Anthony Behin; Rozen Le Panse
Journal:  J Neuromuscul Dis       Date:  2018

Review 9.  International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update.

Authors:  Pushpa Narayanaswami; Donald B Sanders; Gil Wolfe; Michael Benatar; Gabriel Cea; Amelia Evoli; Nils Erik Gilhus; Isabel Illa; Nancy L Kuntz; Janice Massey; Arthur Melms; Hiroyuki Murai; Michael Nicolle; Jacqueline Palace; David Richman; Jan Verschuuren
Journal:  Neurology       Date:  2020-11-03       Impact factor: 9.910
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.